Cumberland Pharmaceuticals (CPIX) Downgraded by ValuEngine to “Sell”

Cumberland Pharmaceuticals (NASDAQ:CPIX) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

Shares of Cumberland Pharmaceuticals (NASDAQ CPIX) traded down $0.29 during trading hours on Monday, hitting $7.31. The stock had a trading volume of 13,172 shares, compared to its average volume of 18,305. Cumberland Pharmaceuticals has a 12 month low of $5.16 and a 12 month high of $7.96. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.81 and a current ratio of 4.18.

Several large investors have recently modified their holdings of the company. Stonepine Capital Management LLC grew its position in shares of Cumberland Pharmaceuticals by 14.7% in the third quarter. Stonepine Capital Management LLC now owns 1,272,191 shares of the specialty pharmaceutical company’s stock valued at $8,982,000 after purchasing an additional 163,024 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Cumberland Pharmaceuticals by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 866,283 shares of the specialty pharmaceutical company’s stock valued at $6,125,000 after purchasing an additional 2,464 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Cumberland Pharmaceuticals by 0.4% in the second quarter. Vanguard Group Inc. now owns 298,635 shares of the specialty pharmaceutical company’s stock valued at $2,111,000 after purchasing an additional 1,180 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Cumberland Pharmaceuticals by 5.2% in the first quarter. Renaissance Technologies LLC now owns 270,240 shares of the specialty pharmaceutical company’s stock valued at $1,875,000 after purchasing an additional 13,240 shares during the last quarter. Finally, Essex Investment Management Co. LLC grew its position in shares of Cumberland Pharmaceuticals by 116.1% in the third quarter. Essex Investment Management Co. LLC now owns 34,494 shares of the specialty pharmaceutical company’s stock valued at $244,000 after purchasing an additional 18,535 shares during the last quarter. 34.44% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/04/cumberland-pharmaceuticals-cpix-downgraded-by-valuengine-to-sell.html.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply